A new drug for advanced breast cancer with severe symptoms
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called SHR-A1811 (a type of targeted therapy) for people with advanced breast cancer that is HER2-low and is causing severe symptoms (visceral crisis). The drug is given alone and aims to control the cancer and relieve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced breast cancer that is HER2-low (a specific type) and cannot be removed by surgery or has spread.
- Your cancer is causing a 'visceral crisis,' meaning it is causing severe organ problems (like liver or lung issues) or a specific blood test shows a high risk situation.
- You have not had more than 3 previous chemotherapy treatments for advanced cancer.
- You have not had treatment with a type of drug called an antibody-drug conjugate (ADC) for any breast cancer.
- You are able to undergo standard single-drug chemotherapy, and your organ function (bone marrow) is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug (SHR-A1811) for breast cancer that has very low HER2 levels. The drug is designed to attack cancer cells with this specific marker, and the study aims to see if it can help slow the cancer's growth.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial tests a new drug combination for people with advanced colorectal cancer that has a specific protein called HER2. The treatment includes a targeted drug (trastuzumab rezetecan) plus chemotherapy and another targeted drug (bevacizumab) to see if it can shrink tumors and help patients live longer.
This trial tests a new sequence of targeted therapies for advanced HER2-positive breast cancer. It aims to see if giving these drugs in a specific order can shrink tumors and delay progression better than current approaches.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Hear when a new HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.